2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 H2 -tulosraportti 8.5. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 H1 -tulosraportti 16.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·21.5.Interesting read: Germany Imported Over 50 Tonnes Of Medical Cannabis In Q1 2026 https://internationalcbc.com/germany-imported-over-50-tonnes-of-medical-cannabis-in-q1-2026/?utm_source=ICBC+Combined+List+Newsletter+and+Outreach&utm_campaign=a71e98d5c3-EMAIL_CAMPAIGN_2025_06_26_02_04_COPY_01&utm_medium=email&utm_term=0_-2f1e7828bf-23717117- 21.5.Interview med CEO: "Medical Cannabis is a movement that can't be stopped" https://www.youtube.com/watch?v=nJ6ZeEhN8CM
- ·11.5.Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, 11 May 2026; First Berlin Equity Research initiation of coverage, 7 May 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The central point in this report is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the United Kingdom is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, which is materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On 7 May 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target among analyst houses to date and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 against First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This fundamentally provides upside risk to both price targets and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap with our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-efficient, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to exceed 10 % already in 2026 (as already demonstrated now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, 7 May 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (9 March 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (9 March 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the gap between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, 11 May 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, 7 May 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)At the earnings call, it doesn't sound unlikely that management indirectly signals an expectation of an EBIT in the range of EUR 10 million for 2026 (no official guidance is given). For the sake of clarity, it is worth noting that EBIT and EBITDA at Cantourage are practically very close to each other. The company is debt-free (no significant interest expenses) and has an asset-light business model without heavy production facilities or large tangible assets to depreciate. In other words: The underlying operating performance is effectively the same (close to), regardless of whether you look at EBITDA or EBIT. In comparison, First Berlin estimates EUR 7.1 million in EBIT for 2026E. If Cantourage actually lands at EUR 10 million, we are talking about a 40 % overshoot of consensus – and that will undoubtedly trigger upward revisions of both price targets and estimates over the coming quarters. Such a result for 2026 is, in our eyes, very positive. It speaks directly to the case we have built: A solid and healthy growth business where the top line continues to grow nicely, while margins and the bottom line shift into a completely different league. This is a combination rarely found in the small/mid-cap segment – and certainly not in a market that is still associated with so much noise and misunderstanding as the European medical cannabis market. In other words, there are a lot of goodies in this paper, both fundamentally, valuation-wise, and strategically.
- ·7.5.Received this morning: "We are pleased to invite you to the Q1 2026 earnings call. During the event, Philip Schetter (CEO) and Monique Jaqqam (CFO) will provide an update on the company’s performance and key developments during the first three months of 2026. Participants will have the opportunity to ask questions and discuss opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: May 11, 2026 Time: 9:00 am (CET) Duration: 1 hour Language: English" Exciting what the first 3 months of the year have brought for Cantourage Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21.5.Interesting read: Germany Imported Over 50 Tonnes Of Medical Cannabis In Q1 2026 https://internationalcbc.com/germany-imported-over-50-tonnes-of-medical-cannabis-in-q1-2026/?utm_source=ICBC+Combined+List+Newsletter+and+Outreach&utm_campaign=a71e98d5c3-EMAIL_CAMPAIGN_2025_06_26_02_04_COPY_01&utm_medium=email&utm_term=0_-2f1e7828bf-23717117
- 21.5.Interview med CEO: "Medical Cannabis is a movement that can't be stopped" https://www.youtube.com/watch?v=nJ6ZeEhN8CM
- ·11.5.Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, 11 May 2026; First Berlin Equity Research initiation of coverage, 7 May 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The central point in this report is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the United Kingdom is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, which is materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On 7 May 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target among analyst houses to date and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 against First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This fundamentally provides upside risk to both price targets and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap with our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-efficient, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to exceed 10 % already in 2026 (as already demonstrated now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, 7 May 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (9 March 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (9 March 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the gap between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, 11 May 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, 7 May 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)At the earnings call, it doesn't sound unlikely that management indirectly signals an expectation of an EBIT in the range of EUR 10 million for 2026 (no official guidance is given). For the sake of clarity, it is worth noting that EBIT and EBITDA at Cantourage are practically very close to each other. The company is debt-free (no significant interest expenses) and has an asset-light business model without heavy production facilities or large tangible assets to depreciate. In other words: The underlying operating performance is effectively the same (close to), regardless of whether you look at EBITDA or EBIT. In comparison, First Berlin estimates EUR 7.1 million in EBIT for 2026E. If Cantourage actually lands at EUR 10 million, we are talking about a 40 % overshoot of consensus – and that will undoubtedly trigger upward revisions of both price targets and estimates over the coming quarters. Such a result for 2026 is, in our eyes, very positive. It speaks directly to the case we have built: A solid and healthy growth business where the top line continues to grow nicely, while margins and the bottom line shift into a completely different league. This is a combination rarely found in the small/mid-cap segment – and certainly not in a market that is still associated with so much noise and misunderstanding as the European medical cannabis market. In other words, there are a lot of goodies in this paper, both fundamentally, valuation-wise, and strategically.
- ·7.5.Received this morning: "We are pleased to invite you to the Q1 2026 earnings call. During the event, Philip Schetter (CEO) and Monique Jaqqam (CFO) will provide an update on the company’s performance and key developments during the first three months of 2026. Participants will have the opportunity to ask questions and discuss opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: May 11, 2026 Time: 9:00 am (CET) Duration: 1 hour Language: English" Exciting what the first 3 months of the year have brought for Cantourage Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 H2 -tulosraportti 8.5. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 H1 -tulosraportti 16.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 |
2026 Q1 -tulosraportti
Vain PDF
58 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 11.5. | ||
2025 H2 -tulosraportti 8.5. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 H1 -tulosraportti 16.10.2025 | ||
2025 Q2 -tulosraportti 11.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21.5.Interesting read: Germany Imported Over 50 Tonnes Of Medical Cannabis In Q1 2026 https://internationalcbc.com/germany-imported-over-50-tonnes-of-medical-cannabis-in-q1-2026/?utm_source=ICBC+Combined+List+Newsletter+and+Outreach&utm_campaign=a71e98d5c3-EMAIL_CAMPAIGN_2025_06_26_02_04_COPY_01&utm_medium=email&utm_term=0_-2f1e7828bf-23717117
- 21.5.Interview med CEO: "Medical Cannabis is a movement that can't be stopped" https://www.youtube.com/watch?v=nJ6ZeEhN8CM
- ·11.5.Cantourage Q1-2026: Profitability breaks through – and a new analyst initiation raises the price target to the highest level to date (Sources: Cantourage Group SE company announcement, 11 May 2026; First Berlin Equity Research initiation of coverage, 7 May 2026) Q1-2026 Highlights – quality over volume - Revenue: EUR 20.6 million (+11.0 % q/q vs. Q4 2025) - EBITDA: EUR 2.2 million with an EBITDA margin of 10.6 % – significant improvement compared to previous quarters - Net cash position: EUR 8.8 million – solid financial platform, still debt-free - Geographical distribution: Germany 51.5 %, UK 41.3 %, Poland 7.3 % The central point in this report is the margin development. Throughout 2025, Cantourage has streamlined its product portfolio towards premium segments and higher-margin categories, and the effect is now unequivocally visible in the figures. The EBITDA margin of 10.6 % in Q1 is a significant improvement from 6.2 % for full 2025 and documents that the company has moved from pure top-line scaling to a phase of real operational leverage. This is qualitative growth, not quantitative. The UK development is the second big message. With 41.3 % of the group's revenue, the United Kingdom is now almost on par with Germany, and as management itself notes, the UK business contributes disproportionately to the group's earnings performance – i.e., with a higher margin than the group as a whole. This is precisely the pan-European diversification we have talked about, which is materializing in the figures. New initiation from First Berlin Equity Research – EUR 11 price target On 7 May 2026 – the day before the Q1 figures were published – First Berlin Equity Research initiated coverage of Cantourage with a BUY recommendation and a price target of EUR 11.00, corresponding to an upside of 76.8 % from the level at the time of initiation (EUR 6.22). This is the highest price target among analyst houses to date and surpasses both NuWays (EUR 10) and Montega (EUR 8-10). The interesting thing is that First Berlin did not have the Q1 figures at hand when they set EUR 11 as the target. With today's Q1 print (EBITDA margin 10.6 % in Q1 against First Berlin's 2026 estimate of 11.5 %), Cantourage is already ahead of the assumptions behind the valuation. This fundamentally provides upside risk to both price targets and estimates, not the opposite. First Berlin's central theses are worth highlighting, as they precisely overlap with our own analysis: 01) "More than a German flower story" – The market underestimates the company's pan-European platform and continues to price it as a pure regulatory binary in the German market. 02) Capital-efficient, scalable, debt-free – The DCF model assumes an 80 % equity ratio, 11.1 % WACC, 2 % terminal growth, and 14.8 % terminal EBIT margin. With these assumptions, the fair value lands at EUR 142 million or EUR 11.00 per share. 03) Margin expansion is the next phase – First Berlin expects the EBITDA margin to exceed 10 % already in 2026 (as already demonstrated now in Q1-2026), and that the gross margin rebounds from 25.1 % (2025E) to 30.1 % (2026E) and further up towards 33 % over time. Valuation check – current price (before open: market cap approx. EUR 77.3 million) With the Q1 figures and First Berlin's initiation, we now have three analyst houses with a consistent BUY recommendation: First Berlin (initiation, 7 May 2026) sets the price target at EUR 11.00 – an upside of approx. +77 % from the current level. NuWays AG (9 March 2026) has a price target of EUR 10.00, corresponding to an upside of approx. +61 %. Montega AG (9 March 2026) is at EUR 8-10, corresponding to an upside of approx. +29-61 %. Our own estimate is EUR 10-12 per share, corresponding to an upside of approx. +61-93 % from today's level. On the Sanity multiple (~4.2x EV/Sales), Cantourage's FY25 revenue of EUR 92.8 million would justify an EV of approx. EUR 390 million against the current market cap of EUR 77.3 million. Even with appropriate haircuts, the gap between the peer multiple and current pricing is still significant. Sources: - Cantourage Group SE Q1-2026 company announcement, 11 May 2026, 08:00 CET - First Berlin Equity Research, "Cantourage Group SE – More Than A German Flower Story", initiation of coverage, 7 May 2026 (BUY, price target EUR 11.00) - NuWays AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 10.00) - Montega AG research update on Cantourage, 9 March 2026 (BUY, price target EUR 8-10) - Share price Cantourage Group SE (HIGH GR / ISIN DE000A3DSV01), Frankfurt Stock Exchange (market cap approx. EUR 77.3 million before open)At the earnings call, it doesn't sound unlikely that management indirectly signals an expectation of an EBIT in the range of EUR 10 million for 2026 (no official guidance is given). For the sake of clarity, it is worth noting that EBIT and EBITDA at Cantourage are practically very close to each other. The company is debt-free (no significant interest expenses) and has an asset-light business model without heavy production facilities or large tangible assets to depreciate. In other words: The underlying operating performance is effectively the same (close to), regardless of whether you look at EBITDA or EBIT. In comparison, First Berlin estimates EUR 7.1 million in EBIT for 2026E. If Cantourage actually lands at EUR 10 million, we are talking about a 40 % overshoot of consensus – and that will undoubtedly trigger upward revisions of both price targets and estimates over the coming quarters. Such a result for 2026 is, in our eyes, very positive. It speaks directly to the case we have built: A solid and healthy growth business where the top line continues to grow nicely, while margins and the bottom line shift into a completely different league. This is a combination rarely found in the small/mid-cap segment – and certainly not in a market that is still associated with so much noise and misunderstanding as the European medical cannabis market. In other words, there are a lot of goodies in this paper, both fundamentally, valuation-wise, and strategically.
- ·7.5.Received this morning: "We are pleased to invite you to the Q1 2026 earnings call. During the event, Philip Schetter (CEO) and Monique Jaqqam (CFO) will provide an update on the company’s performance and key developments during the first three months of 2026. Participants will have the opportunity to ask questions and discuss opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: May 11, 2026 Time: 9:00 am (CET) Duration: 1 hour Language: English" Exciting what the first 3 months of the year have brought for Cantourage Group.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt